US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alumis Inc.

8.54

-1.3000-13.21%

Post-market: 8.26-0.2800-3.28%19:14 EDT

Volume:596.15K

Turnover:5.23M

Market Cap:464.64M

PE:-0.55

High:9.70

Open:8.72

Low:7.66

Close:9.84

Loading ...

Overview Company News Filings

Alumis Inc: Alumis & ACELYRIN's Combined Pro Forma Cash Position of About $737 Mln as of Dec 31, 2024, Provides Runway Into 2027

THOMSON REUTERS

Alumis Inc: Combined Company Will Operate Under Alumis Name With Current Alumis Executive Team

THOMSON REUTERS

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Oppenheimer Initiates Coverage on Alumis With Outperform Rating, $32 Price Target

MT Newswires Live

Alumis initiated with an Outperform at Oppenheimer

Alumis Strengthens Leadership Team With Key Appointments

THOMSON REUTERS

Alumis Strengthens Leadership Team with Key Appointments

Alumis Price Target Maintained With a $26.00/Share by HC Wainwright & Co.

Owning 32% shares,hedge funds owners seem interested in Alumis Inc. (NASDAQ:ALMS),

Simply Wall St.

Alumis Price Target Maintained With a $26.00/Share by HC Wainwright & Co.

BRIEF-Alumis Announces Positive Phase 1 Data For Cns Penetrant Tyk2 Inhibitor, A-005

Alumis Inc: Data Support Advancement to Phase 2 Clinical Trial in Multiple Sclerosis, Anticipated in 2H 2025

THOMSON REUTERS

Alumis Inc: Maximal Tyk2 Inhibition Achieved With Favorable Pharmacokinetic Profile in CNS and Periphery

THOMSON REUTERS

Alumis Announces Positive Phase 1 Data for CNS Penetrant Tyk2 Inhibitor, a-005

THOMSON REUTERS

Alumis Inc: a-005 Was Well Tolerated and Demonstrated Ability to Cross Blood-Brain Barrier

THOMSON REUTERS

Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005

Buy Rating for Alumis Inc. Driven by Promising ESK-001 Clinical Results and Reduced Competition

Alumis Inc.: Promising Clinical Advancements and Strategic Positioning Drive Buy Rating

Alumis Inc. Reports Q3 2024 Financial Results and Advances Clinical Programs

Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ALMS/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ALMS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALMS\",,,,,undefined,":{"symbol":"ALMS","market":"US","secType":"STK","nameCN":"Alumis Inc.","latestPrice":8.54,"timestamp":1743710400000,"preClose":9.84,"halted":0,"volume":596148,"hourTrading":{"tag":"盘后","latestPrice":8.26,"preClose":8.54,"latestTime":"19:14 EDT","volume":1664,"amount":13995.6501,"timestamp":1743722065088},"delay":0,"floatShares":19951689,"shares":54407327,"eps":-15.598233,"marketStatus":"Not Yet Opened","change":-1.3,"latestTime":"04-03 16:00:00 EDT","open":8.72,"high":9.7,"low":7.6609,"amount":5225637.235308,"amplitude":0.207226,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-15.598233,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1743753600000},"marketStatusCode":0,"adr":0,"listingDate":1719547200000,"exchange":"NASDAQ","adjPreClose":9.84,"preHourTrading":{"tag":"盘前","latestPrice":9,"preClose":9.84,"latestTime":"09:29 EDT","volume":2262,"amount":21217.725125999998,"timestamp":1743686955852},"postHourTrading":{"tag":"盘后","latestPrice":8.26,"preClose":8.54,"latestTime":"19:14 EDT","volume":1664,"amount":13995.6501,"timestamp":1743722065088},"volumeRatio":0.425637},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALMS\",,,,,undefined,":{"symbol":"ALMS","floatShares":19951689,"roa":"-87.31%","roe":"-198.66%","lyrEps":-72.082961,"volumeRatio":0.425637,"shares":54407327,"dividePrice":0,"high":9.7,"amplitude":0.207226,"preClose":9.84,"low":7.6609,"week52Low":3.18,"pbRate":"1.79","week52High":13.53,"institutionHeld":0,"latestPrice":8.54,"eps":-15.598233,"divideRate":0,"volume":596148,"delay":0,"ttmEps":-15.598233,"open":8.72,"prevYearClose":7.86,"prevWeekClose":5.64,"prevMonthClose":6.14,"prevQuarterClose":6.14,"fiveDayClose":4.7,"twentyDayClose":5.1,"sixtyDayClose":8.79},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALMS\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2509778105","title":"Alumis Inc: Alumis & ACELYRIN's Combined Pro Forma Cash Position of About $737 Mln as of Dec 31, 2024, Provides Runway Into 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2509778105","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509778105?lang=en_us&edition=fundamental","pubTime":"2025-02-07 05:15","pubTimestamp":1738876500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250206:nTUA6JLCGT:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLRN","BK4139","ALMS","BK4007"],"gpt_icon":0},{"id":"2509292781","title":"Alumis Inc: Combined Company Will Operate Under Alumis Name With Current Alumis Executive Team","url":"https://stock-news.laohu8.com/highlight/detail?id=2509292781","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509292781?lang=en_us&edition=fundamental","pubTime":"2025-02-07 05:15","pubTimestamp":1738876500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250206:nTUA6JLCGT:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ALMS","SLRN","BK4139"],"gpt_icon":0},{"id":"2509781045","title":"Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2509781045","media":"GlobeNewswire","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509781045?lang=en_us&edition=fundamental","pubTime":"2025-02-07 05:15","pubTimestamp":1738876500,"startTime":"0","endTime":"0","summary":"Topline data from Phase 3 ONWARD trials for Alumis’ ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on track for readout in 2026. Evaluation underway of development plan for ACELYRIN’s lonigutamab to confirm differentiation in a capital efficient manner. Alumis and ACELYRIN stockholders to own ~55% and ~45%, respectively, of combined company on a fully diluted basis. Bruce Cozadd, Chair of the ACELYRIN Board of Directors and member of the Board Transaction Committee, said, “This merger represents the culmination of a thorough strategic review process by our Board and management team to determine the best and most value-maximizing path forward for ACELYRIN. We are confident that Alumis is the right partner to optimize the development of lonigutamab and together deliver long-term stockholder value.”“We are pleased to join with Alumis and further advance our mission of develop","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alumis-acelyrin-merge-creating-stage-211500228.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SLRN","ALMS","BK4007","SSI"],"gpt_icon":0},{"id":"2507362835","title":"Oppenheimer Initiates Coverage on Alumis With Outperform Rating, $32 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2507362835","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507362835?lang=en_us&edition=fundamental","pubTime":"2025-01-30 21:06","pubTimestamp":1738242386,"startTime":"0","endTime":"0","summary":"Alumis (ALMS) has an average rating of Buy and mean price target of $30.33, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and re","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OPY","ALMS"],"gpt_icon":0},{"id":"2507429526","title":"Alumis initiated with an Outperform at Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2507429526","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507429526?lang=en_us&edition=fundamental","pubTime":"2025-01-30 20:06","pubTimestamp":1738238788,"startTime":"0","endTime":"0","summary":"Oppenheimer initiated coverage of Alumis (ALMS) with an Outperform rating and $32 price target The company is focused on delivering “class-leading”...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alumis-initiated-with-an-outperform-at-oppenheimer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alumis-initiated-with-an-outperform-at-oppenheimer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OPY","ALMS"],"gpt_icon":0},{"id":"2506351806","title":"Alumis Strengthens Leadership Team With Key Appointments","url":"https://stock-news.laohu8.com/highlight/detail?id=2506351806","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506351806?lang=en_us&edition=fundamental","pubTime":"2025-01-28 21:00","pubTimestamp":1738069201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250128:nTUA6SMJM2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"2506513567","title":"Alumis Strengthens Leadership Team with Key Appointments","url":"https://stock-news.laohu8.com/highlight/detail?id=2506513567","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506513567?lang=en_us&edition=fundamental","pubTime":"2025-01-28 21:00","pubTimestamp":1738069200,"startTime":"0","endTime":"0","summary":"Jack Danilkowicz appointed as Chief Commercial Officer; bringing extensive experience successfully planning and executing commercial strategies at global biopharmaceutical companiesSara Klein promoted","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/28/3016314/0/en/Alumis-Strengthens-Leadership-Team-with-Key-Appointments.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TISI","BK4120","ALMS","BK4007"],"gpt_icon":0},{"id":"2501233514","title":"Alumis Price Target Maintained With a $26.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2501233514","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501233514?lang=en_us&edition=fundamental","pubTime":"2025-01-06 20:02","pubTimestamp":1736164920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALMS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 06, 2025 07:02 ET (12:02 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"gpt_icon":0},{"id":"2494231781","title":"Owning 32% shares,hedge funds owners seem interested in Alumis Inc. (NASDAQ:ALMS),","url":"https://stock-news.laohu8.com/highlight/detail?id=2494231781","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494231781?lang=en_us&edition=fundamental","pubTime":"2024-12-28 21:27","pubTimestamp":1735392472,"startTime":"0","endTime":"0","summary":"Significantly high institutional ownership implies Alumis' stock price is sensitive to their trading actions. A total of 4 investors have a majority stake in the company with 53% ownership. Using data from analyst forecasts alongside ownership research, one can better assess the future performance of a company. Every investor in Alumis Inc.  should be aware of the most powerful shareholder groups. With 32% stake, hedge funds possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises .In the chart below, we zoom in on the different ownership groups of Alumis.NasdaqGS:ALMS Earnings and Revenue Growth December 28th 2024. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/owning-32-shares-hedge-funds-132752215.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B3QW5Z07.USD","QLD","MNQmain","LU2210149790.SGD","BK4588","IE00BKPKM429.USD","BK4007","IE00B64PRP62.GBP","BK4112","USJW.SI","LU2210150020.SGD","USAW.SI","SQQQ","NQmain","BK4585","LU2095319765.USD","IE00BGHQF748.EUR",".IXIC","QID","ALMS","PSQ","TSYW.SI","NVIW.SI","TQQQ","NDAQ"],"gpt_icon":1},{"id":"2492938410","title":"Alumis Price Target Maintained With a $26.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2492938410","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492938410?lang=en_us&edition=fundamental","pubTime":"2024-12-20 20:50","pubTimestamp":1734699000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALMS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 20, 2024 07:50 ET (12:50 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"gpt_icon":0},{"id":"2492120452","title":"BRIEF-Alumis Announces Positive Phase 1 Data For Cns Penetrant Tyk2 Inhibitor, A-005","url":"https://stock-news.laohu8.com/highlight/detail?id=2492120452","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492120452?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:23","pubTimestamp":1734614635,"startTime":"0","endTime":"0","summary":"BRIEF-Alumis Announces Positive Phase 1 Data For Cns Penetrant Tyk2 Inhibitor, A-005Dec 19 (Reuters) - Alumis Inc ALMS.O:ALUMIS ANNOUNCES POSITIVE PHASE 1 DATA FOR CNS PENETRANT TYK2 INHIBITOR, A-005A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nTUABZ385M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALMS"],"gpt_icon":0},{"id":"2492712798","title":"Alumis Inc: Data Support Advancement to Phase 2 Clinical Trial in Multiple Sclerosis, Anticipated in 2H 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2492712798","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492712798?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:00","pubTimestamp":1734613200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nTUABZ385M:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ALMS"],"gpt_icon":0},{"id":"2492512749","title":"Alumis Inc: Maximal Tyk2 Inhibition Achieved With Favorable Pharmacokinetic Profile in CNS and Periphery","url":"https://stock-news.laohu8.com/highlight/detail?id=2492512749","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492512749?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:00","pubTimestamp":1734613200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nTUABZ385M:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ALMS"],"gpt_icon":0},{"id":"2492276211","title":"Alumis Announces Positive Phase 1 Data for CNS Penetrant Tyk2 Inhibitor, a-005","url":"https://stock-news.laohu8.com/highlight/detail?id=2492276211","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492276211?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:00","pubTimestamp":1734613200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nTUABZ385M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"2492112769","title":"Alumis Inc: a-005 Was Well Tolerated and Demonstrated Ability to Cross Blood-Brain Barrier","url":"https://stock-news.laohu8.com/highlight/detail?id=2492112769","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492112769?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:00","pubTimestamp":1734613200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nTUABZ385M:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"2492312729","title":"Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005","url":"https://stock-news.laohu8.com/highlight/detail?id=2492312729","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492312729?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:00","pubTimestamp":1734613200,"startTime":"0","endTime":"0","summary":"– A-005 was well tolerated and demonstrated ability to cross blood-brain barrier – – Maximal TYK2 inhibition achieved with favorable pharmacokinetic profile in CNS and periphery – – Data support advan","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/19/2999795/0/en/Alumis-Announces-Positive-Phase-1-Data-for-CNS-Penetrant-TYK2-Inhibitor-A-005.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","IE00BKVL7J92.USD","LU2357305700.SGD","CSF","LU1989772840.SGD","LU0795875169.SGD","LU0795875086.SGD","LU1548497426.USD","LU1989772923.USD","LU0320765646.SGD","PK","LU0158827948.USD","LU2111349929.HKD","LU0225283273.USD","CNS","PD","LU0912757837.SGD","LU1074936037.SGD","LU2089284900.SGD","LU0106831901.USD","LU0106261372.USD","BK4516","BK4007","LU1363072403.SGD","BK4588","LU2028103732.USD","BK4127","LU2271345857.HKD","LU0098860793.USD","LU2089283258.USD","BK4585","BK4218","BK4504","LU2023251221.USD","LU1720051108.HKD","LU1169590202.USD","LU0314104364.USD","LU1162221912.USD","LU1732799900.SGD","LU1732800096.USD","IE00BZ1G4Q59.USD","BK4581","LU0971096721.USD","LU1668664300.SGD","BK4534","LU0267386448.USD","BK4023","LU1169589451.USD","LU0158827781.USD","BK4181"],"gpt_icon":0},{"id":"2485243974","title":"Buy Rating for Alumis Inc. Driven by Promising ESK-001 Clinical Results and Reduced Competition","url":"https://stock-news.laohu8.com/highlight/detail?id=2485243974","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485243974?lang=en_us&edition=fundamental","pubTime":"2024-11-21 14:18","pubTimestamp":1732169893,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst Thomas Smith has maintained their bullish stance on ALMS stock, giving a Buy rating on November 15. Thomas Smith’s rating ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-for-alumis-inc-driven-by-promising-esk-001-clinical-results-and-reduced-competition?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-for-alumis-inc-driven-by-promising-esk-001-clinical-results-and-reduced-competition?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALMS"],"gpt_icon":0},{"id":"2484627829","title":"Alumis Inc.: Promising Clinical Advancements and Strategic Positioning Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2484627829","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484627829?lang=en_us&edition=fundamental","pubTime":"2024-11-19 14:45","pubTimestamp":1731998739,"startTime":"0","endTime":"0","summary":"Brian Skorney, an analyst from Robert W. Baird, maintained the Buy rating on Alumis Inc. (ALMS – Research Report). The associated price target rema...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/alumis-inc-promising-clinical-advancements-and-strategic-positioning-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/alumis-inc-promising-clinical-advancements-and-strategic-positioning-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALMS"],"gpt_icon":0},{"id":"2483687305","title":"Alumis Inc. Reports Q3 2024 Financial Results and Advances Clinical Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2483687305","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483687305?lang=en_us&edition=fundamental","pubTime":"2024-11-16 12:02","pubTimestamp":1731729755,"startTime":"0","endTime":"0","summary":"Alumis Inc. ( ($ALMS) ) has released its Q3 earnings. Here is a breakdown of the information Alumis Inc. presented to its investors. Alumis Inc., a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alumis-inc-reports-q3-2024-financial-results-and-advances-clinical-programs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alumis-inc-reports-q3-2024-financial-results-and-advances-clinical-programs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ALMS"],"gpt_icon":0},{"id":"2483258337","title":"Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483258337","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483258337?lang=en_us&edition=fundamental","pubTime":"2024-11-15 05:05","pubTimestamp":1731618300,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Nov.  14, 2024  (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/14/2981606/0/en/Alumis-Presents-Data-Highlighting-ESK-001-s-Potential-as-a-High-efficacy-Oral-Treatment-for-Systemic-Lupus-Erythematosus-SLE-at-ACR-Convergence-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","BK4110","SLE","ALMS","ACR","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":4,"totalSize":93}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALMS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-19","symbol":"ALMS","fiscalQuarterEnding":"2024/12","expectedEps":-1.39,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742356800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-11-13","symbol":"ALMS","fiscalQuarterEnding":"2024/09","expectedEps":-1.64,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-1.73}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALMS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ALMS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6,"buy":0.4,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6,"analysts":5,"updateTime":1738296000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ALMS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ALMS","date":"2025-04-02","current":-1.338766,"percent":0.795455,"low":-5.220865,"twenty":-3.508814,"median":-2.146452,"eighty":-1.301332,"high":-0.660137,"avg":-2.458039,"sd":1.054291,"marketCap":393909047},"quantilePoints":[{"date":"2024-06-28","current":-5.220865,"twenty":-5.220865,"median":-5.220865,"eighty":-5.220865,"marketCap":881360393},{"date":"2024-07-05","current":-3.577828,"twenty":-4.31182,"median":-3.851156,"eighty":-3.577828,"marketCap":603991092},{"date":"2024-07-12","current":-3.798947,"twenty":-4.001025,"median":-3.825051,"eighty":-3.577828,"marketCap":641319297},{"date":"2024-07-15","current":-3.405847,"twenty":-3.980142,"median":-3.798947,"eighty":-3.577828,"marketCap":574958044},{"date":"2024-08-02","current":-4.08515,"twenty":-4.063676,"median":-3.825051,"eighty":-3.577828,"marketCap":689634611},{"date":"2024-08-09","current":-3.930629,"twenty":-4.063676,"median":-3.914533,"eighty":-3.58397,"marketCap":663549141},{"date":"2024-08-16","current":-3.699952,"twenty":-4.025518,"median":-3.855481,"eighty":-3.617622,"marketCap":699416662},{"date":"2024-08-23","current":-3.709695,"twenty":-3.973459,"median":-3.817957,"eighty":-3.659922,"marketCap":701258562},{"date":"2024-08-30","current":-3.67516,"twenty":-3.943506,"median":-3.741353,"eighty":-3.65762,"marketCap":694730166},{"date":"2024-09-06","current":-3.390241,"twenty":-3.930629,"median":-3.739914,"eighty":-3.608539,"marketCap":640870897},{"date":"2024-09-13","current":-3.240587,"twenty":-3.915649,"median":-3.699952,"eighty":-3.511116,"marketCap":612581180},{"date":"2024-09-20","current":-3.272245,"twenty":-3.914533,"median":-3.679477,"eighty":-3.395997,"marketCap":618565543},{"date":"2024-09-27","current":-3.444923,"twenty":-3.859807,"median":-3.655014,"eighty":-3.33556,"marketCap":651207524},{"date":"2024-10-04","current":-2.886598,"twenty":-3.851156,"median":-3.617387,"eighty":-3.295269,"marketCap":545665119},{"date":"2024-10-11","current":-2.961425,"twenty":-3.850149,"median":-3.577828,"eighty":-3.211808,"marketCap":559809977},{"date":"2024-10-18","current":-3.200296,"twenty":-3.817957,"median":-3.47802,"eighty":-3.18015,"marketCap":604964718},{"date":"2024-10-25","current":-3.444923,"twenty":-3.798947,"median":-3.465068,"eighty":-3.200296,"marketCap":651207524},{"date":"2024-10-31","current":-3.231953,"twenty":-3.752872,"median":-3.462191,"eighty":-3.209506,"marketCap":610949081},{"date":"2024-11-08","current":-3.367218,"twenty":-3.741353,"median":-3.447801,"eighty":-3.218715,"marketCap":636518633},{"date":"2024-11-15","current":-2.144174,"twenty":-3.741353,"median":-3.444923,"eighty":-3.209506,"marketCap":511972947},{"date":"2024-11-22","current":-2.15101,"twenty":-3.739051,"median":-3.433411,"eighty":-3.073089,"marketCap":513605166},{"date":"2024-11-29","current":-2.109995,"twenty":-3.736748,"median":-3.419021,"eighty":-3.008623,"marketCap":503811848},{"date":"2024-12-06","current":-1.964163,"twenty":-3.720056,"median":-3.405847,"eighty":-2.970059,"marketCap":468991158},{"date":"2024-12-13","current":-1.989228,"twenty":-3.703849,"median":-3.378729,"eighty":-2.667081,"marketCap":474975964},{"date":"2024-12-20","current":-1.966442,"twenty":-3.691984,"median":-3.312536,"eighty":-2.153744,"marketCap":469535232},{"date":"2024-12-27","current":-1.916313,"twenty":-3.685521,"median":-3.301025,"eighty":-2.142807,"marketCap":457565620},{"date":"2025-01-03","current":-1.873019,"twenty":-3.682067,"median":-3.286635,"eighty":-2.0626,"marketCap":447228227},{"date":"2025-01-10","current":-1.752253,"twenty":-3.67516,"median":-3.266489,"eighty":-2.0029,"marketCap":418392344},{"date":"2025-01-17","current":-1.775039,"twenty":-3.672282,"median":-3.247782,"eighty":-1.966442,"marketCap":423833077},{"date":"2025-01-24","current":-1.497048,"twenty":-3.658468,"median":-3.227637,"eighty":-1.954138,"marketCap":357456138},{"date":"2025-01-31","current":-1.531227,"twenty":-3.654166,"median":-3.211808,"eighty":-1.919959,"marketCap":365617237},{"date":"2025-02-07","current":-1.501605,"twenty":-3.631778,"median":-3.162882,"eighty":-1.882133,"marketCap":358544284},{"date":"2025-02-14","current":-1.162092,"twenty":-3.62163,"median":-3.070787,"eighty":-1.832004,"marketCap":277477367},{"date":"2025-02-21","current":-1.168928,"twenty":-3.613315,"median":-3.018984,"eighty":-1.784609,"marketCap":279109587},{"date":"2025-02-28","current":-1.064112,"twenty":-3.590112,"median":-2.978693,"eighty":-1.743594,"marketCap":254082217},{"date":"2025-03-07","current":-1.162092,"twenty":-3.577828,"median":-2.970059,"eighty":-1.696654,"marketCap":277477367},{"date":"2025-03-14","current":-1.045883,"twenty":-3.561975,"median":-2.844868,"eighty":-1.612801,"marketCap":249729630},{"date":"2025-03-21","current":-0.660137,"twenty":-3.530406,"median":-2.358363,"eighty":-1.527581,"marketCap":194234157},{"date":"2025-03-28","current":-0.869088,"twenty":-3.513232,"median":-2.153288,"eighty":-1.493402,"marketCap":255714436},{"date":"2025-04-02","current":-1.338766,"twenty":-3.508814,"median":-2.146452,"eighty":-1.301332,"marketCap":393909047}],"updateTime":1743739987219}}}